← BioLineRx Ltd.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ($1.4m) |
($1.7m)
-25.22%
|
($1.4m)
+19.55%
|
($857k)
+37.08%
|
($840k)
+1.98%
|
$0
+100.00%
|
$0 | $4.8m |
$28.9m
+502.92%
|
$1.2m
-95.92%
|
$1.4m
+18.81%
|
|
| License revenues | — | — | — | — | — | — | $0 | $4.6m | $22.9m | $1.2m | — | |
| Revenue From Interest | — | — | — | — | — | — | $694k | $2.0m | $1.8m | $1.1m | — | |
| Product sales, net | — | — | — | — | — | — | $0 | $190k | $6.0m | $0 | — | |
| Cost of Goods and Services Sold | ($5.5m) |
($5.5m)
+1.44%
|
($8.2m)
-49.80%
|
($8.8m)
-7.86%
|
$947k
+110.72%
|
$0
-100.00%
|
$0 | $3.7m |
$9.3m
+150.89%
|
$230k
-97.52%
|
$291k
+26.52%
|
|
| COST OF REVENUES | $0 | $0 | ($3.7m) |
($9.3m)
-150.89%
|
($230k)
+97.52%
|
$291k
+226.52%
|
||||||
| Gross Profit | — | — | — | — | — | $0 | $0 | $1.1m |
$19.7m
+1675.90%
|
$950k
-95.17%
|
$1.1m
+16.95%
|
|
| Research and development | $11.2m | $19.5m | $19.8m | $23.4m | $18.2m | $19.5m | $17.6m | $12.5m | $9.1m | $8.1m | $9.0m | |
| Selling, General and Administrative Expense | $4.0m | $4.0m | $4.4m | $3.8m | $3.9m | $4.3m | $5.1m | $6.3m | $6.3m | $3.1m | $3.8m | |
| SALES AND MARKETING EXPENSES | ($1.4m) | ($1.7m) | ($1.4m) | ($857k) | ($840k) | ($1.0m) | ($6.5m) | ($25.3m) | ($23.6m) | $0 | ||
| Operating expenses: | ||||||||||||
| OPERATING LOSS | ($16.5m) |
($25.2m)
-52.85%
|
($25.6m)
-1.45%
|
($28.1m)
-9.79%
|
($22.9m)
+18.44%
|
($24.8m)
-8.07%
|
($29.2m)
-17.68%
|
($49.7m)
-70.44%
|
($20.4m)
+58.93%
|
($10.3m)
+49.59%
|
($10.9m)
-5.96%
|
|
| Interest Expense | — | — | — | — | — | — | $1.8m | $2.1m | $9.1m | $1.3m | $1.1m | |
| Interest Income | $480k | $1.2m | $719k | $777k | $236k | $559k | $694k | $2.1m | $1.9m | $1.5m | $1.0m | |
| Other Income | $7k | — | $244k | — | — | — | — | — | — | — | — | |
| NON-OPERATING INCOME (EXPENSES), NET | $214k | ($260k) | $2.4m | $4.2m | ($5.7m) | ($1.8m) | $5.7m | ($10.8m) | $18.4m | $8.1m | ||
| Income Tax Expense Continuing Operations | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | |
| Basic Earnings (Loss) Per Share | — | — | — | — | ($0) | ($0) | ($0.03) | ($0.06) | ($0.01) | $0.00 | $0.00 | |
| Diluted Earnings (Loss) Per Share | — | — | — | — | ($0) | ($0) | ($0.03) | ($0.06) | ($0.01) | $0.00 | $0.00 | |
| WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF BASIC LOSS PER ORDINARY SHARE | 56.1m | 90.0m | 108.6m | 146.4m | 252.8m | 662.9m | 774.0m | 963.4m | 1.2b | 2.5b | ||
| WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF DILUTED LOSS PER ORDINARY SHARE | 963.4m | 1.2b | 2.5b | |||||||||
| Additional Financial Items | ||||||||||||
| Applicable Tax Rate | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Depreciation And Amortisation Expense | $452k | $452k | $424k | $862k | $864k | $660k | $615k | $583k | $431k | $495k | $28k | |
| Employee Benefits Expense | $523k | $563k | $618k | $580k | $668k | $744k | $792k | — | — | — | — | |
| Finance Costs | $22k | $21k | $473k | $2.3m | $1.6m | $1.0m | $2.2m | $2.2m | $9.1m | $1.3m | — | |
| Finance Income | $480k | $1.2m | $719k | $777k | $236k | $559k | $694k | $2.1m | $1.9m | $1.5m | — | |
| Professional Fees Expense | $1.1m | $1.3m | $1.1m | $1.2m | $1.0m | $1.1m | $1.2m | $2.0m | $2.0m | $1.3m | — | |
| Profit Loss Attributable To Noncontrolling Interests | — | — | — | — | — | — | — | — | — | $6.0m | — | |
| Profit Loss From Operating Activities | ($16.5m) | ($25.2m) | ($25.6m) | ($28.1m) | ($22.9m) | ($24.8m) | ($29.2m) | ($49.7m) | ($20.4m) | ($10.3m) | — | |
| IMPAIRMENT OF INTANGIBLE ASSETS | $0 | $0 | ($6.7m) | ($1.0m) | $0 | |||||||
| FINANCIAL EXPENSES | ($22k) | ($21k) | ($473k) | ($2.3m) | ($1.6m) | ($1.0m) | ($2.2m) | ($2.2m) | ($9.1m) | ($1.3m) | ||
| LOSS AND COMPREHENSIVE LOSS | ($15.8m) | ($24.4m) | ($23.0m) | ($25.4m) | ($30.0m) | ($27.1m) | ($25.0m) | ($60.6m) | ($9.2m) | ($2.0m) | ||
| To owners of the Company | — | — | — | — | — | — | — | ($60.6m) | ($9.2m) | ($1.2m) | — | |
| To non-controlling interests | — | — | — | — | — | — | — | $0 | $0 | ($851k) | — | |
| LOSS PER ORDINARY SHARE – BASIC ATTRIBUTABLE TO OWNERS OF THE COMPANY | ($0) | ($0) | ($0) | ($0) | ($0) | $0 | ||||||
| LOSS PER ORDINARY SHARE – DILUTED ATTRIBUTABLE TO OWNERS OF THE COMPANY | ($0) | ($0) | ($0) | ($0) | ($0) | $0 | ||||||
| Net Foreign Exchange Loss | — | — | — | — | — | — | $346k | $0 | $0 | — | — | |
| Total comprehensive income | — | — | — | — | — | — | — | ($60.6m) | ($9.2m) | ($2.0m) | — |